167 related articles for article (PubMed ID: 38525060)
1. Recent advances in DDAH1 inhibitor design and discovery: insights from structure-activity relationships and X-ray crystal structures.
Doman AJ; Perkins MV; Tommasi S; Mangoni AA; Nair PC
RSC Adv; 2024 Mar; 14(14):9619-9630. PubMed ID: 38525060
[TBL] [Abstract][Full Text] [Related]
2. Chemical similarities and differences among inhibitors of nitric oxide synthase, arginase and dimethylarginine dimethylaminohydrolase-1: Implications for the design of novel enzyme inhibitors modulating the nitric oxide pathway.
Doman AJ; Tommasi S; Perkins MV; McKinnon RA; Mangoni AA; Nair PC
Bioorg Med Chem; 2022 Oct; 72():116970. PubMed ID: 36063653
[TBL] [Abstract][Full Text] [Related]
3. Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).
Reddy KRK; Dasari C; Duscharla D; Supriya B; Ram NS; Surekha MV; Kumar JM; Ummanni R
Angiogenesis; 2018 Feb; 21(1):79-94. PubMed ID: 29150732
[TBL] [Abstract][Full Text] [Related]
4. Dimethylarginine dimethylaminohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt.
Zhang P; Hu X; Xu X; Chen Y; Bache RJ
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):890-7. PubMed ID: 21212404
[TBL] [Abstract][Full Text] [Related]
5. Dissection, Optimization, and Structural Analysis of a Covalent Irreversible DDAH1 Inhibitor.
Burstein-Teitelbaum G; Er JAV; Monzingo AF; Tuley A; Fast W
Biochemistry; 2018 Jul; 57(30):4574-4582. PubMed ID: 29983043
[TBL] [Abstract][Full Text] [Related]
6. Novel Cellularly Active Inhibitor Regresses DDAH1 Induced Prostate Tumor Growth by Restraining Tumor Angiogenesis through Targeting DDAH1/ADMA/NOS Pathway.
Kami Reddy KR; Dasari C; Vandavasi S; Natani S; Supriya B; Jadav SS; Sai Ram N; Kumar JM; Ummanni R
ACS Comb Sci; 2019 Apr; 21(4):241-256. PubMed ID: 30673277
[TBL] [Abstract][Full Text] [Related]
7. Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance.
Tommasi S; Elliot DJ; Hulin JA; Lewis BC; McEvoy M; Mangoni AA
Sci Rep; 2017 Jun; 7(1):2871. PubMed ID: 28588208
[TBL] [Abstract][Full Text] [Related]
8. A role for Dimethylarginine Dimethylaminohydrolase 1 (DDAH1) in mammalian development.
Breckenridge RA; Kelly P; Nandi M; Vallance PJ; Ohun TJ; Leiper J
Int J Dev Biol; 2010; 54(1):215-20. PubMed ID: 19757398
[TBL] [Abstract][Full Text] [Related]
9. Dimethylarginine Dimethylaminohydrolase - 1 expression is increased under tBHP-induced oxidative stress regulates nitric oxide production in PCa cells attenuates mitochondrial ROS-mediated apoptosis.
Asha Parveen SM; Kami Reddy KR; Ummanni R
Nitric Oxide; 2023 Sep; 138-139():70-84. PubMed ID: 37423418
[TBL] [Abstract][Full Text] [Related]
10. Repetitive ischemia increases myocardial dimethylarginine dimethylaminohydrolase 1 expression.
Zhang P; Fassett JT; Zhu G; Li J; Hu X; Xu X; Chen Y; Bache RJ
Vasc Med; 2017 Jun; 22(3):179-188. PubMed ID: 28145161
[TBL] [Abstract][Full Text] [Related]
11. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine.
Hu X; Atzler D; Xu X; Zhang P; Guo H; Lu Z; Fassett J; Schwedhelm E; Böger RH; Bache RJ; Chen Y
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1540-6. PubMed ID: 21493890
[TBL] [Abstract][Full Text] [Related]
12. Dimethylarginine dimethylaminohydrolase-1 contributes to exercise-induced cardiac angiogenesis in mice.
Shi X; Luo X; Xu X
Biosci Trends; 2020 May; 14(2):115-122. PubMed ID: 32238672
[TBL] [Abstract][Full Text] [Related]
13. Esomeprazole covalently interacts with the cardiovascular enzyme dimethylarginine dimethylaminohydrolase: Insights into the cardiovascular risk of proton pump inhibitors.
Smith CA; Ebrahimpour A; Novikova L; Farina D; Bailey AO; Russell WK; Jain A; Saltzman AB; Malovannaya A; Prasad BVV; Hu L; Ghebre YT
Biochim Biophys Acta Gen Subj; 2022 Aug; 1866(8):130149. PubMed ID: 35472493
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine.
Hu X; Xu X; Zhu G; Atzler D; Kimoto M; Chen J; Schwedhelm E; Lüneburg N; Böger RH; Zhang P; Chen Y
Circulation; 2009 Dec; 120(22):2222-9. PubMed ID: 19917889
[TBL] [Abstract][Full Text] [Related]
15. Small molecule inhibition of DDAH1 significantly attenuates triple negative breast cancer cell vasculogenic mimicry in vitro.
Hulin JA; Tommasi S; Elliot D; Mangoni AA
Biomed Pharmacother; 2019 Mar; 111():602-612. PubMed ID: 30611984
[TBL] [Abstract][Full Text] [Related]
16. Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.
Xu X; Zhang P; Kwak D; Fassett J; Yue W; Atzler D; Hu X; Liu X; Wang H; Lu Z; Guo H; Schwedhelm E; Böger RH; Chen P; Chen Y
Basic Res Cardiol; 2017 Aug; 112(5):55. PubMed ID: 28819685
[TBL] [Abstract][Full Text] [Related]
17. MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1.
Hulin JA; Tommasi S; Elliot D; Hu DG; Lewis BC; Mangoni AA
Sci Rep; 2017 Oct; 7(1):13996. PubMed ID: 29070803
[TBL] [Abstract][Full Text] [Related]
18. HIF-1α and Nrf2 regulates hypoxia induced overexpression of DDAH1 through promoter activation in prostate cancer.
Parveen SMA; Natani S; Sruthi K K ; Khilar P; Ummanni R
Int J Biochem Cell Biol; 2022 Jun; 147():106232. PubMed ID: 35644470
[TBL] [Abstract][Full Text] [Related]
19. Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas.
Boult JK; Walker-Samuel S; Jamin Y; Leiper JM; Whitley GS; Robinson SP
J Pathol; 2011 Nov; 225(3):344-52. PubMed ID: 21590769
[TBL] [Abstract][Full Text] [Related]
20. Dimethylarginine dimethylaminohydrolase-2 deficiency promotes vascular regeneration and attenuates pathological angiogenesis.
Lange C; Mowat F; Sayed H; Mehad M; Duluc L; Piper S; Luhmann U; Nandi M; Kelly P; Smith A; Ali R; Leiper J; Bainbridge J
Exp Eye Res; 2016 Jun; 147():148-155. PubMed ID: 27181226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
